Sign in Subscribe
Vaccines

Bharat Biotech's iNCOVACC Covid Vaccine Approved for Public Use, Priced at Rs 800 for Private Markets

Strategic Insights

— 1 min read

Bharat Biotech International Limited has announced the approval and pricing of its COVID-19 intranasal vaccine, iNCOVACC, marking a significant milestone in the global fight against the pandemic. The vaccine, priced at Rs 800 (excluding GST) for private markets and Rs 325 (excluding GST) for government supplies, will be rolled out in the fourth week of January 2023. Developed in partnership with Washington University, St. Louis, iNCOVACC is the world's first intranasal vaccine to receive approval for the primary two-dose schedule, as well as a heterologous booster dose.

Key Takeaways:

  • iNCOVACC, the COVID-19 intranasal vaccine developed by Bharat Biotech, has been approved for public use in India.
  • The vaccine will be priced at Rs 800 (excluding GST) for private markets and Rs 325 (excluding GST) for government supplies.
  • iNCOVACC has been approved for the primary two-dose schedule and as a heterologous booster dose, marking a significant milestone in the fight against COVID-19.
  • Phase-III trials of iNCOVACC involved approximately 3100 subjects, and heterologous booster dose studies were conducted on 875 subjects.
  • iNCOVACC was developed in partnership with Washington University, St. Louis, which designed and developed the recombinant adenoviral vectored construct and evaluated its efficacy in pre-clinical studies.
  • Krishna Ella, Executive Chairman of Bharat Biotech, highlighted the vaccine's capabilities for rapid product development, scale-up, and easy and painless immunization during public health emergencies.

Statistics:

  • Approximately 3100 subjects were involved in the Phase-III trials of iNCOVACC.
  • 875 subjects participated in the heterologous booster dose studies of iNCOVACC.
  • iNCOVACC is priced at Rs 800 (excluding GST) for private markets and Rs 325 (excluding GST) for government supplies.

Sources:

  • Bharat Biotech International Limited press release
  • Central Drugs Standard Control Organisation (CDSCO) approval
  • Washington University, St. Louis
  • Afternoon Despatch & Courier

Read more